Filing Details

Accession Number:
0001209191-21-026293
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-09 17:53:43
Reporting Period:
2021-04-07
Accepted Time:
2021-04-09 17:53:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1678660 Prelude Therapeutics Inc PRLD Pharmaceutical Preparations (2834) 811384762
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1824631 Christopher Pierce C/O Prelude Therapeutics Incorporated
200 Powder Mill Road
Wilmington DE 19803
Evp And Chief Of Business Oper No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-07 828 $1.89 4,578 No 4 A Direct
Common Stock Disposition 2021-04-07 828 $40.08 3,750 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-04-07 828 $0.00 828 $1.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,818 2030-03-26 No 4 M Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  3. The stock option is fully vested.